Skip to main content
SpringerLink
Log in

Proinflammatory cytokines and osteoporosis

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Experimental studies indicate that the proinflammatory cytokines interleukin-1, interleukin-6, and tumor necrosis factor-α are important regulators of bone resorption and may play an important role in age- and estrogen deficiency-related bone loss. Although the observation of accelerated bone loss in patients with inflammatory disorders supports this mechanism, the role of cytokines in the etiology of osteoporosis has yet to be determined. Elucidation of this potential relationship could not only provide clinicians with an additional tool to identify patients at risk for osteoporosis, but may also inform the development of cytokine-blocking therapies as potential interventions to curb bone loss. Although some epidemiologic studies suggest increases in proinflammatory cytokines are associated with decreased bone mass and greater fracture risk, the totality of evidence is limited and provides no clear indication of which cytokines may be most important for bone health. Additional studies are required to establish if inflammation is an important risk factor for osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jilka RL: Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 1998, 23:75–81.

    Article  CAS  PubMed  Google Scholar 

  2. Hofbauer LC, Khosla S, Dunstan CR, et al.: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2–12.

    Article  CAS  PubMed  Google Scholar 

  3. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207–227.

    Article  CAS  PubMed  Google Scholar 

  4. Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279–302.

    Article  CAS  PubMed  Google Scholar 

  5. Pacifici R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996, 11:1043–1051.

    CAS  PubMed  Google Scholar 

  6. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115–137.

    Article  CAS  PubMed  Google Scholar 

  7. Manolagas SC, Kousteni S, Jilka RL: Sex steroids and bone. Recent Prog Horm Res 2002, 57:385–409.

    Article  CAS  PubMed  Google Scholar 

  8. Goldring SR: Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003, 73:97–100.

    Article  CAS  PubMed  Google Scholar 

  9. Sinigaglia L, Varenna M, Girasole G, Bianchi G: Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006, 32:631–658.

    Article  PubMed  Google Scholar 

  10. Haugeberg G, Conaghan PG, Quinn M, Emery P: Bone loss in active early rheumatoid arthritis patients treated with infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a twelve-month randomized, double blind, placebo-controlled study. Ann Rheum Dis 2009 Apr 21 (Epub ahead of print).

  11. Visvanathan S, van der Heijde D, Deodhar A, et al.: Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175–182.

    Article  CAS  PubMed  Google Scholar 

  12. Briot K, Gossec L, Kolta S, et al.: Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008, 35:855–861.

    CAS  PubMed  Google Scholar 

  13. Pazianas M, Rhim AD, Weinberg AM, et al.: The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn’s disease. Ann N Y Acad Sci 2006, 1068:543–556.

    Article  CAS  PubMed  Google Scholar 

  14. Pacifici R, Rifas L, Teitelbaum S, et al.: Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A 1987, 84:4616–4620.

    Article  CAS  PubMed  Google Scholar 

  15. Zheng SX, Vrindts Y, Lopez M, et al.: Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 1997, 26:63–71.

    Article  CAS  PubMed  Google Scholar 

  16. Khosla S, Peterson JM, Egan K, et al.: Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 1994, 79:707–711.

    Article  CAS  PubMed  Google Scholar 

  17. Zarrabeitia MT, Riancho JA, Amado JA, et al.: Cytokine production by peripheral blood cells in postmenopausal osteoporosis. Bone Miner 1991, 14:161–167.

    Article  CAS  PubMed  Google Scholar 

  18. Hustmyer FG, Walker E, Yu XP, et al.: Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res 1993, 8:51–59.

    Article  CAS  PubMed  Google Scholar 

  19. Papadopoulos NG, Georganas K, Skoutellas V, et al.: Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol 1997, 16:162–165.

    Article  CAS  PubMed  Google Scholar 

  20. Giuliani N, Sansoni P, Girasole G, et al.: Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol 2001, 36:547–557.

    Article  CAS  PubMed  Google Scholar 

  21. Tamura T, Udagawa N, Takahashi N, et al.: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993, 90:11924–11928.

    Article  CAS  PubMed  Google Scholar 

  22. Kania DM, Binkley N, Checovich M, et al.: Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc 1995, 43:236–239.

    CAS  PubMed  Google Scholar 

  23. McKane WR, Khosla S, Peterson JM, et al.: Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res 1994, 9:1313–1318.

    CAS  PubMed  Google Scholar 

  24. Hogasen AK, Nordsletten L, Aasen AO, Falch JA: There is no difference in spontaneous and 17 beta-estradiol-induced interleukin-1 beta release by peripheral blood mononuclear cells from nonosteoporotic women with different rates of early postmenopausal bone loss. J Clin Endocrinol Metab 1995, 80:2480–2484.

    Article  CAS  PubMed  Google Scholar 

  25. Ding C, Parameswaran V, Udayan R, et al.: Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008, 93:1952–1958.

    Article  CAS  PubMed  Google Scholar 

  26. Salamone LM, Whiteside T, Friberg D, et al.: Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int 1998, 63:466–470.

    Article  CAS  PubMed  Google Scholar 

  27. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, et al.: Cytokines and bone loss in a 5-year longitudinal study: hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2000, 15:1545–1554.

    Article  CAS  PubMed  Google Scholar 

  28. Abrahamsen B, Bendtzen K, Beck-Nielsen H: Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone 1997, 20:251–258.

    Article  CAS  PubMed  Google Scholar 

  29. Pacifici R, Rifas L, McCracken R, et al.: Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A 1989, 86:2398–2402.

    Article  CAS  PubMed  Google Scholar 

  30. Pacifici R, Vannice JL, Rifas L, Kimble RB: Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J Clin Endocrinol Metab 1993, 77:1135–1141.

    Article  CAS  PubMed  Google Scholar 

  31. Bismar H, Diel I, Ziegler R, Pfeilschifter J: Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995, 80:3351–3355.

    Article  CAS  PubMed  Google Scholar 

  32. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al.: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001, 86:2032–2042.

    Article  CAS  PubMed  Google Scholar 

  33. McLean RR, Roubenoff R, Hannan MT, et al.: Elevated production of interleukin 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) by peripheral blood mononuclear cells (PBMC) is associated with increased hip fracture risk in elders: the Framingham Osteoporosis Study. J Bone Miner Res 2008, 23(Suppl):S79.

    Google Scholar 

  34. Cauley JA, Danielson ME, Boudreau RM, et al.: Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007, 22:1088–1095.

    Article  CAS  PubMed  Google Scholar 

  35. Aderka D, Engelmann H, Shemer-Avni Y, et al.: Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992, 11:157–159.

    CAS  PubMed  Google Scholar 

  36. Bouxsein ML, Karasik D: Bone geometry and skeletal fragility. Curr Osteoporos Rep 2006, 4:49–56.

    Article  PubMed  Google Scholar 

  37. Lauretani F, Bandinelli S, Russo CR, et al.: Correlates of bone quality in older persons. Bone 2006, 39:915–921.

    Article  CAS  PubMed  Google Scholar 

  38. Russo CR, Lauretani F, Seeman EB, et al.: Structural adaptations to bone loss in aging men and women. Bone 2006, 38:112–118.

    Article  PubMed  Google Scholar 

  39. Xing Z, Gauldie J, Cox G, et al.: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311–320.

    Article  CAS  PubMed  Google Scholar 

  40. Fattori E, Cappelletti M, Costa P, et al.: Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994, 180:1243–1250.

    Article  CAS  PubMed  Google Scholar 

  41. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.

    Article  CAS  PubMed  Google Scholar 

  42. Weinhold B, Ruther U: Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J 1997, 327(Pt 2):425–429.

    CAS  PubMed  Google Scholar 

  43. Moshage H: Cytokines and the hepatic acute phase response. J Pathol 1997, 181:257–266.

    Article  CAS  PubMed  Google Scholar 

  44. Koh JM, Khang YH, Jung CH, et al.: Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int 2005, 16:1263–1271.

    Article  CAS  PubMed  Google Scholar 

  45. Kim BJ, Yu YM, Kim EN, et al.: Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women. Clin Endocrinol (Oxf) 2007, 67:152–158.

    Article  CAS  Google Scholar 

  46. Pasco JA, Kotowicz MA, Henry MJ, et al.: High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006, 296:1353–1355.

    Article  CAS  PubMed  Google Scholar 

  47. Schett G, Kiechl S, Weger S, et al.: High-sensitivity Creactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006, 166:2495–2501.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Aging Research, Hebrew SeniorLife, 1200 Centre Street, Boston, MA, 02131, USA

    Robert R. McLean

Authors
  1. Robert R. McLean
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert R. McLean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLean, R.R. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 7, 134–139 (2009). https://doi.org/10.1007/s11914-009-0023-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-009-0023-2

Keywords

Search

Navigation